Impact Capital Partners LLC Acquires 444 Shares of AstraZeneca PLC $AZN

Impact Capital Partners LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 15.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,282 shares of the company’s stock after acquiring an additional 444 shares during the period. Impact Capital Partners LLC’s holdings in AstraZeneca were worth $229,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its holdings in AstraZeneca by 30.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock worth $1,003,124,000 after buying an additional 3,224,251 shares during the period. Boston Partners boosted its holdings in AstraZeneca by 35.9% in the 1st quarter. Boston Partners now owns 5,036,645 shares of the company’s stock worth $368,712,000 after buying an additional 1,329,166 shares during the period. Ameriprise Financial Inc. boosted its holdings in AstraZeneca by 5.6% in the 1st quarter. Ameriprise Financial Inc. now owns 4,942,367 shares of the company’s stock worth $364,283,000 after buying an additional 261,064 shares during the period. Swedbank AB boosted its holdings in AstraZeneca by 20.8% in the 2nd quarter. Swedbank AB now owns 4,077,554 shares of the company’s stock worth $284,939,000 after buying an additional 701,779 shares during the period. Finally, WCM Investment Management LLC boosted its holdings in AstraZeneca by 7.3% in the 1st quarter. WCM Investment Management LLC now owns 4,003,070 shares of the company’s stock worth $295,387,000 after buying an additional 272,537 shares during the period. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a report on Wednesday, July 9th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Stock Up 10.0%

Shares of NASDAQ:AZN opened at $84.36 on Thursday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $84.61. The company has a 50-day moving average price of $77.59 and a 200 day moving average price of $73.00. The company has a market cap of $261.63 billion, a price-to-earnings ratio of 31.71, a PEG ratio of 1.41 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. During the same quarter last year, the firm earned $1.24 EPS. The firm’s revenue for the quarter was up 16.1% compared to the same quarter last year. As a group, equities research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were given a dividend of $0.505 per share. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca’s dividend payout ratio (DPR) is 37.97%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.